Tag: Merck

All

FDA Approves Vaxneuvance Pneumococcal Vaccine for Infants, Children

The FDA has expanded the approval for Merck's Vaxneuvance for prevention of invasive disease caused by Streptococcus pneumoniae to include children 6 weeks through 17 years of age.

FDA Authorizes Merck Molnupiravir Antiviral COVID Pill
Merck VaxNeuvance Pneumococcal Vaccine Approved in EU
Success of COVID Antiviral Pills Hinges on Access to Speedy and Accurate Tests
Merck to License COVID-19 Antiviral to Drugmakers in Other Companies
Merck’s COVID-19 Antiviral Pill Cut Prevented Mortality, Cut Hospitalization Risks in Half
FDA: New Merck Pneumonia Vaccine OK’d
Merk’s Experimental Lung Cancer Drug Fails Trial

All

Positive Data for Merck’s Pneumococcal Conjugate Vaccine Candidate

Two Phase 3 studies of Merck's investigational 15-valent pneumococcal conjugate vaccine met their primary immunogenicity objectives.

Merck’s Sublingual Allergen Ragwitek Approved By FDA For Ragweed Allergies
FDA Approves Merck’s Sublingual Allergen Grastek

Tag: Merck

All

FDA Approves Vaxneuvance Pneumococcal Vaccine for Infants, Children

FDA Authorizes Merck Molnupiravir Antiviral COVID Pill

Merck VaxNeuvance Pneumococcal Vaccine Approved in EU

Success of COVID Antiviral Pills Hinges on Access to Speedy and Accurate Tests

Merck to License COVID-19 Antiviral to Drugmakers in Other Companies

Merck’s COVID-19 Antiviral Pill Cut Prevented Mortality, Cut Hospitalization Risks in Half

FDA: New Merck Pneumonia Vaccine OK’d

Merk’s Experimental Lung Cancer Drug Fails Trial

All

Positive Data for Merck’s Pneumococcal Conjugate Vaccine Candidate

Merck’s Sublingual Allergen Ragwitek Approved By FDA For Ragweed Allergies

FDA Approves Merck’s Sublingual Allergen Grastek

All

Sorry, No Posts Found

Sorry, No Posts Found